Pharmacogenetics of tardive dyskinesia in schizophrenia: The role ofCHRM1andCHRM2muscarinic receptors

Boiko, Anastasiia S.; Ivanova, Svetlana A.; Pozhidaev, Ivan V; Freidin, Maxim B.; Osmanova, D.; Fedorenko, Olga Yu; Semke, A.; Бохан, Н. А.; Wilffert, Bob; Loonen, Anton J. M.

doi:10.1080/15622975.2018.1548780

Cited by 15 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patient selection has been previously described. 17 We recruited patients from three psychiatric hospitals located in the Tomsk, Kemerovo, and Chita oblasts (regions) of Siberia, Russia. The inclusion criteria were a clinical diagnosis of schizophrenia, according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10: F20), and age 18-75 years old.…”

Section: Patients and Methods Patientsmentioning

confidence: 99%

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia

Pozhidaev

Boiko

Loonen

et al. 2020

TACG

Self Cite

View full text Add to dashboard Cite

Background: Previous studies have linked muscarinic M4 receptors (CHRM4) to schizophrenia. Specifically, the rs2067482 polymorphism was found to be highly associated with this disease. Purpose: To test whether rs2067482 and rs72910092 are potential risk factors for schizophrenia and/or pharmacogenetic markers for antipsychotic-induced tardive dyskinesia. Patients and Methods: We genotyped DNA of 449 patients with schizophrenia and 134 healthy controls for rs2067482 and rs72910092 polymorphisms of the CHRM4 gene with the use of the MassARRAY ® System by Agena Bioscience. Mann-Whitney test was used to compare qualitative traits and χ 2 test was used for categorical traits. Results: The frequency of genotypes and alleles of rs72910092 did not differ between patients with schizophrenia and control subjects. We did not reveal any statistical differences for both rs2067482 and rs72910092 between schizophrenia patients with and without tardive dyskinesia. The frequency of the C allele of the polymorphic variant rs2067482 was significantly higher in healthy persons compared to patients with schizophrenia (OR=0.51, 95% CI [0.33-0.80]; p=0.003). Accordingly, the CC genotype was found significantly more often in healthy persons compared to patients with schizophrenia (OR=0.49, 95% CI [0.31-0.80]; p=0.010). Conclusion: Our study found the presence of the minor allele (T) of rs2067482 variant being associated with schizophrenia. We argue that the association of rs2067482 with schizophrenia may be via its regulatory effect on some other gene with protein kinase C and casein Kknase substrate in neurons 3 (PACSIN3) as a possible candidate. Neither rs2067482 nor rs72910092 is associated with tardive dyskinesia.

show abstract

Section: Patients and Methods Patientsmentioning

confidence: 99%

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia

Pozhidaev

Boiko

Loonen

et al. 2020

TACG

Self Cite

View full text Add to dashboard Cite

show abstract

“…The study population was previously described (Boiko et al, 2019;Levchenko et al, 2019). Patients were recruited who were, or had been, using antipsychotic medication for more than 3 months and were on a stable dosage for at least 3 months prior to entry.…”

Section: Patientsmentioning

confidence: 99%

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

Pozhidaev

Paderina

Fedorenko

et al. 2020

Front. Mol. Neurosci.

Self Cite

View full text Add to dashboard Cite

Background: Tardive dyskinesia (TD) is a common side effect of antipsychotic treatment. This movement disorder consists of orofacial and limb-truncal components. The present study is aimed at investigating the role of serotonin receptors (HTR) in modulating tardive dyskinesia by genotyping patients with schizophrenia. Methods: A set of 29 SNPs of genes of serotonin receptors HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B, and HTR6 was studied in a population of 449 Caucasians (226 females and 223 males) with verified clinical diagnosis of schizophrenia (according to ICD-10: F20). Five SNPs were excluded because of low minor allele frequency or for not passing the Hardy-Weinberg equilibrium test. Affinity of antipsychotics to 5-HT2 receptors was defined according to previous publications. Genotyping was carried out with SEQUENOM Mass Array Analyzer 4. Results: Statistically significant associations of rs1928040 of HTR2A gene in groups of patients with orofacial type of TD and total diagnosis of TD was found for alleles, and a statistical trend for genotypes. Moreover, statistically significant associations were discovered in the female group for rs1801412 of HTR2C for alleles and genotypes. Excluding patients who used HTR2A, respectively, HTR2C antagonists changed little to the associations of HTR2A polymorphisms, but caused a major change of the magnitude of the association of HTR2C variants. Due to the low patient numbers, these sub-analyses did not have significant results. Conclusion: We found significant associations in rs1928040 of HTR2A and for rs1801412 of X-bound HTR2C in female patients. The associations were particularly related to the orofacial type of TD. Excluding patients using relevant antagonists particularly affected rs1801412, but not rs1928040-related associations. This suggest

show abstract

“…S. Boiko и соавт. (2019) обнаружили пограничную статистически значимую связь между двумя ОНВ rs2061174 и rs1824024 гена мускаринового рецептора M 2 (CHRM2) и риском развития АП-индуцированной ТД [26]. Однако логистический регрессионный анализ показал, что это наблюдение также может быть связано с хорошо известными факторами риска ТД, такими как пол, возраст, длительность заболевания и дозы АП [71].…”

Section: ген мускаринового рецептора M 2 Chrm2unclassified

“…A. S. Boiko и соавт. (2019) сделали вывод, что в нашей популяции пациентов была обнаружена довольно слабая связь между распространенностью ТД и двумя вариантами гена CHRM2 [26].…”

Section: ген мускаринового рецептора M 2 Chrm2unclassified

Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia

Vaiman¹,

Шнайдер²,

Neznanov³

et al. 2020

Neuromuscular Diseases

View full text Add to dashboard Cite

Introduction. Drug-induced dyskinesia is an iatrogenic undesirable side reaction from the extrapyramidal system that occurs during the administration of drugs, most often antipsychotics in patients with schizophrenia. At the end of the 20 th century, studies were conducted on the search for candidate genes and the carriage of single nucleotide variants of antipsychotics-induced tardive dyskinesia. Purpose of the study – to analyze research results reflecting candidate genes and their single nucleotide variants associated with antipsychotic-induced tardive dyskinesia. Materials and methods. We searched for full-text publications in Russian and English in the eLIBRARY, PubMed, Web of Science, Springer databases using keywords (tardive dyskinesia, drug-induced tardive dyskinesia, antipsychotics, antipsychotics, typical antipsychotics, atypical antipsychotics, genes, polymorphisms) and combined searches for words over the past decade. Results. The lecture discusses candidate genes encoding proteins/enzymes involved in the pharmacodynamics and pharmacokinetics of antipsychotics Conclusion. Timely identification of individual genetic characteristics of the patient can contribute to the development of diagnostic test systems and in the future selection of the safest and most effective antipsychotic therapy.

show abstract

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role ofCHRM1andCHRM2muscarinic receptors

Cited by 15 publications

References 30 publications

<p>Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia</p>

<p>Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia</p>

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia

Contact Info

Product

Resources

About